Gene info: ID 5527

Gene: PPP2R5C

GENE ID: 5527

Synonyms: B56G|B56gamma|PR61G

Description: protein phosphatase 2 regulatory subunit B'gamma

Gene type: protein-coding

Location: 14q32.31

dbXrefs: Ensembl:ENSG00000078304 MIM:601645 Vega:OTTHUMG00000171597 UniprotKB:Q13362

RefSeq: NG_047069.1

Retrived from: SNP Mapped

SNPs: 1 ANCO-SNPs

Phenotype: ND

# Publications: 0

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 1.993e-2 (AD) 3.421e-1 (ND)

ANCO-SNPs

SNP ID	Position	Alleles	Trait	Variation Type
rs1612684	chr14:101909875 (GRCh38.p7)	G>T	nicotine dependence	SNV(Single Nucleotide Variation)

DNA Methylation

Probe	Locus(GRCh37)	Gene	Region	p-val	Trait	PubMed ID
cg17904575	chr14:102290370	PPP2R5C		5.000e-8	Smoking	27651444

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
RNF11	0.958
PRKAR1A	0.941
SCOC	0.936
BTBD1	0.936
RAB6A	0.935
RPRD1A	0.93
SUB1	0.929
CCNY	0.928
PJA2	0.928
CHMP3	0.927

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
OR4F5	-0.711
OR4F29	-0.703
CSAG1	-0.346
MTRNR2L10	-0.326
MTRNR2L6	-0.32
MAGEA12	-0.285
EVC2	-0.285
MTRNR2L3	-0.281
S100A12	-0.279
MTRNR2L9	-0.275

ID	Drug Name	Drug Type	CAS Num	Status	Role
DB02506	2,6,8-Trimethyl-3-Amino-9-Benzyl-9-Methoxynonanoic Acid	Small Molecule		Experimental	Target
DB06905	(2S,3S,4E,6E,8S,9S)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid	Small Molecule		Experimental	Target

ID	Drug Name	Action	PubMed
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP2R5C mRNA"	27188386
C012606	4-vinyl-1-cyclohexene dioxide	4-vinyl-1-cyclohexene dioxide affects the expression of PPP2R5C mRNA	20829426
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP2R5C mRNA"	27188386
D000082	Acetaminophen	Acetaminophen affects the expression of PPP2R5C mRNA	17562736
D000638	Amiodarone	Amiodarone results in increased expression of PPP2R5C mRNA	19774075
D018501	Antirheumatic Agents	Antirheumatic Agents results in decreased expression of PPP2R5C mRNA	24449571
D001151	Arsenic	Arsenic affects the methylation of PPP2R5C gene	25304211
D001280	Atrazine	Atrazine results in increased expression of PPP2R5C mRNA	22378314
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of PPP2R5C mRNA	20064835\|2623829
D001564	Benzo(a)pyrene	AHR protein affects the reaction [Benzo(a)pyrene affects the expression of PPP2R5C mRNA]	22228805
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of PPP2R5C mRNA	19770486
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of PPP2R5C mRNA	22228805
D015123	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of PPP2R5C mRNA"	19150397\|2001819
C006780	bisphenol A	bisphenol A affects the expression of PPP2R5C mRNA	25181051
D002166	Camptothecin	PPP2R5C protein promotes the reaction [Camptothecin results in increased expression of H2AFX protein modified form]	25772433
D002166	Camptothecin	PPP2R5C protein results in increased susceptibility to Camptothecin	25772433
D002220	Carbamazepine	Carbamazepine affects the expression of PPP2R5C mRNA	24752500
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of PPP2R5C mRNA	27339419
C024989	coenzyme Q10	coenzyme Q10 inhibits the reaction [Lipopolysaccharides results in increased expression of PPP2R5C mRNA]	21370964
D003471	Cuprizone	Cuprizone results in decreased expression of PPP2R5C mRNA	26577399
D013759	Dronabinol	Dronabinol results in decreased expression of PPP2R5C mRNA	16616335
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in decreased expression of PPP2R5C mRNA	21266533
D002945	Cisplatin	[Cisplatin co-treated with jinfukang] results in decreased expression of PPP2R5C mRNA	27392435
D004008	Diclofenac	Diclofenac affects the expression of PPP2R5C mRNA	24752500
C000944	dicrotophos	dicrotophos results in decreased expression of PPP2R5C mRNA	28302478
D004051	Diethylhexyl Phthalate	Diethylhexyl Phthalate results in increased expression of PPP2R5C mRNA	19850644
D004051	Diethylhexyl Phthalate	PPARA protein promotes the reaction [Diethylhexyl Phthalate results in increased expression of PPP2R5C mRNA]	19850644
D004112	Dimercaprol	Dimercaprol inhibits the reaction [Mustard Gas results in decreased expression of PPP2R5C mRNA]	16377760
D004221	Disulfiram	Disulfiram results in decreased expression of PPP2R5C mRNA	20530235
D004791	Enzyme Inhibitors	[Enzyme Inhibitors results in decreased activity of OGA protein] which results in increased O-linked glycosylation of PPP2R5C protein	23301498
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in decreased expression of PPP2R5C mRNA	23550701
D018120	Finasteride	Finasteride results in increased expression of PPP2R5C mRNA	24136188
D019833	Genistein	Genistein results in increased expression of PPP2R5C mRNA	26865667
D005839	Gentamicins	Gentamicins results in increased expression of PPP2R5C mRNA	22061828
D017313	Fenretinide	Fenretinide results in decreased expression of PPP2R5C mRNA	28973697
D017313	Fenretinide	Fenretinide results in increased expression of PPP2R5C mRNA	28973697
D015759	Ionomycin	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of PPP2R5C mRNA	25613284
C544151	jinfukang	[Cisplatin co-treated with jinfukang] results in decreased expression of PPP2R5C mRNA	27392435
C544151	jinfukang	jinfukang results in decreased expression of PPP2R5C mRNA	27392435
D007854	Lead	Lead affects the splicing of PPP2R5C mRNA	28903495
D008070	Lipopolysaccharides	coenzyme Q10 inhibits the reaction [Lipopolysaccharides results in increased expression of PPP2R5C mRNA]	21370964
D008070	Lipopolysaccharides	Lipopolysaccharides results in increased expression of PPP2R5C mRNA	21370964
D008727	Methotrexate	PPP2R5C protein affects the susceptibility to Methotrexate	16217747
C004925	methylmercuric chloride	methylmercuric chloride results in decreased expression of PPP2R5C mRNA	28001369
C004925	methylmercuric chloride	methylmercuric chloride results in increased expression of PPP2R5C mRNA	23179753\|2800136
D008741	Methyl Methanesulfonate	Methyl Methanesulfonate results in increased expression of PPP2R5C mRNA	23649840
D018817	N-Methyl-3,4-methylenedioxyamphetamine	"N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of PPP2R5C mRNA"	26251327
D008769	Methylnitronitrosoguanidine	PPP2R5C protein results in increased susceptibility to Methylnitronitrosoguanidine	25772433
D016685	Mitomycin	PPP2R5C protein results in increased susceptibility to Mitomycin	25772433
D009151	Mustard Gas	Dimercaprol inhibits the reaction [Mustard Gas results in decreased expression of PPP2R5C mRNA]	16377760
D009151	Mustard Gas	Mustard Gas results in decreased expression of PPP2R5C mRNA	16377760
D037742	Nanotubes, Carbon	"Nanotubes, Carbon results in increased expression of PPP2R5C mRNA"	25554681
C016030	pantogab	pantogab results in increased expression of PPP2R5C mRNA	17379144
D010416	Pentachlorophenol	Pentachlorophenol results in increased expression of PPP2R5C mRNA	23892564
C006253	pirinixic acid	[pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of PPP2R5C mRNA	19710929
C006253	pirinixic acid	pirinixic acid results in increased expression of PPP2R5C mRNA	17426115\|1830175
C009277	sodium arsenate	sodium arsenate results in increased expression of PPP2R5C mRNA	21795629
D012969	Sodium Fluoride	Sodium Fluoride results in decreased expression of PPP2R5C mRNA	27862939
D012999	Soman	Soman results in decreased expression of PPP2R5C mRNA	19281266
D053260	Soot	Soot results in decreased expression of PPP2R5C mRNA	23634900
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of PPP2R5C mRNA	21570461
D013755	Tetradecanoylphorbol Acetate	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of PPP2R5C mRNA	25613284
D013893	Thiram	Thiram results in decreased expression of PPP2R5C mRNA	20530235
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in increased expression of PPP2R5C mRNA	28065790
D014050	Toluene	Toluene affects the expression of PPP2R5C mRNA	21827849
C012589	trichostatin A	"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP2R5C mRNA"	27188386
C012589	trichostatin A	trichostatin A results in increased expression of PPP2R5C mRNA	24935251\|2627250
C015559	trimellitic anhydride	trimellitic anhydride results in increased expression of PPP2R5C mRNA	19042947
D014635	Valproic Acid	Valproic Acid results in decreased expression of PPP2R5C mRNA	23179753
D014635	Valproic Acid	Valproic Acid results in increased methylation of PPP2R5C gene	29154799

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005515	protein binding	-	IPI	1328865 7592815 16239230 16456541 16580887 17245430 17540176 18782753 19156129 19915589 21460856 25241761 27173435 28174209 28330616
GO:0019888	protein phosphatase regulator activity	-	NAS	8703017
GO:0072542	protein phosphatase activator activity	-	IBA	21873635

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0006470	protein dephosphorylation	CONTRIBUTES_TO	IBA	21873635
GO:0007165	signal transduction	-	NAS	8703017
GO:0008285	negative regulation of cell proliferation	-	IDA	17245430
GO:0014066	regulation of phosphatidylinositol 3-kinase signaling	-	TAS	-
GO:0031952	regulation of protein autophosphorylation	-	IBA	21873635
GO:0043161	proteasome-mediated ubiquitin-dependent protein catabolic process	-	IMP	16717086
GO:0043666	regulation of phosphoprotein phosphatase activity	-	IEA	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000159	protein phosphatase type 2A complex	-	IBA	21873635
GO:0000159	protein phosphatase type 2A complex	-	IDA	17174897
GO:0000159	protein phosphatase type 2A complex	-	NAS	8703017
GO:0000775	chromosome, centromeric region	-	IDA	16580887
GO:0005634	nucleus	-	IBA	21873635
GO:0005634	nucleus	-	IDA	8703017
GO:0005654	nucleoplasm	-	IDA	-
GO:0005654	nucleoplasm	-	TAS	-
GO:0005794	Golgi apparatus	-	IDA	-
GO:0005829	cytosol	-	IBA	21873635
GO:0005829	cytosol	-	IDA	-
GO:0005829	cytosol	-	TAS	-

KEGG ID	KEGG Term
hsa03015	mRNA surveillance pathway
hsa04114	Oocyte meiosis
hsa04310	Wnt signaling pathway

Reactome ID	Reactome Term	Evidence
R-HSA-109582	Hemostasis	TAS
R-HSA-1257604	PIP3 activates AKT signaling	TAS
R-HSA-1280218	Adaptive Immune System	TAS
R-HSA-141424	Amplification of signal from the kinetochores	TAS
R-HSA-141444	Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal	TAS
R-HSA-162582	Signal Transduction	TAS
R-HSA-162582	Signal Transduction	IEA
R-HSA-1640170	Cell Cycle	TAS
R-HSA-1643685	Disease	TAS
R-HSA-168256	Immune System	TAS
R-HSA-194315	Signaling by Rho GTPases	TAS
R-HSA-195253	Degradation of beta-catenin by the destruction complex	TAS
R-HSA-195258	RHO GTPase Effectors	TAS
R-HSA-195721	Signaling by WNT	TAS
R-HSA-195721	Signaling by WNT	IEA
R-HSA-196299	Beta-catenin phosphorylation cascade	TAS
R-HSA-199418	Negative regulation of the PI3K/AKT network	TAS
R-HSA-201681	TCF dependent signaling in response to WNT	TAS
R-HSA-201681	TCF dependent signaling in response to WNT	IEA
R-HSA-212436	Generic Transcription Pathway	TAS
R-HSA-2467813	Separation of Sister Chromatids	TAS
R-HSA-2500257	Resolution of Sister Chromatid Cohesion	TAS
R-HSA-2555396	Mitotic Metaphase and Anaphase	TAS
R-HSA-3700989	Transcriptional Regulation by TP53	TAS
R-HSA-388841	Costimulation by the CD28 family	TAS
R-HSA-389513	CTLA4 inhibitory signaling	TAS
R-HSA-418346	Platelet homeostasis	TAS
R-HSA-432142	Platelet sensitization by LDL	TAS
R-HSA-4641262	Disassembly of the destruction complex and recruitment of AXIN to the membrane	TAS
R-HSA-4641262	Disassembly of the destruction complex and recruitment of AXIN to the membrane	IEA
R-HSA-4791275	Signaling by WNT in cancer	TAS
R-HSA-4839735	AXIN mutants destabilize the destruction complex, activating WNT signaling	TAS
R-HSA-4839743	phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex	TAS
R-HSA-4839744	truncated APC mutants destabilize the destruction complex	TAS
R-HSA-4839748	AMER1 mutants destabilize the destruction complex	TAS
R-HSA-5339716	Misspliced GSK3beta mutants stabilize beta-catenin	TAS
R-HSA-5358747	S33 mutants of beta-catenin aren't phosphorylated	TAS
R-HSA-5358749	S37 mutants of beta-catenin aren't phosphorylated	TAS
R-HSA-5358751	S45 mutants of beta-catenin aren't phosphorylated	TAS
R-HSA-5358752	T41 mutants of beta-catenin aren't phosphorylated	TAS
R-HSA-5467337	APC truncation mutants have impaired AXIN binding	TAS
R-HSA-5467340	AXIN missense mutants destabilize the destruction complex	TAS
R-HSA-5467348	Truncations of AMER1 destabilize the destruction complex	TAS
R-HSA-5633007	Regulation of TP53 Activity	TAS
R-HSA-5663202	Diseases of signal transduction	TAS
R-HSA-5663220	RHO GTPases Activate Formins	TAS
R-HSA-5673000	RAF activation	TAS
R-HSA-5673001	RAF/MAP kinase cascade	TAS
R-HSA-5675221	Negative regulation of MAPK pathway	TAS
R-HSA-5683057	MAPK family signaling cascades	TAS
R-HSA-5684996	MAPK1/MAPK3 signaling	TAS
R-HSA-6804757	Regulation of TP53 Degradation	TAS
R-HSA-6806003	Regulation of TP53 Expression and Degradation	TAS
R-HSA-6811558	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	TAS
R-HSA-68877	Mitotic Prometaphase	TAS
R-HSA-68882	Mitotic Anaphase	TAS
R-HSA-68886	M Phase	TAS
R-HSA-69278	Cell Cycle, Mitotic	TAS
R-HSA-69618	Mitotic Spindle Checkpoint	TAS
R-HSA-69620	Cell Cycle Checkpoints	TAS
R-HSA-73857	RNA Polymerase II Transcription	TAS
R-HSA-74160	Gene expression (Transcription)	TAS
R-HSA-9006925	Intracellular signaling by second messengers	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal